Biotech Startups

VascVersa develops a platform for vascular stem cell therapy and cell therapy manufacturing, serving the advanced therapies and clinical development sectors in vascular biology.

1 investor

Vasomune is a clinical-stage biotech company developing therapeutic treatments for vascular and immune-related diseases. The company focuses on bringing drug candidates like AV-001 from laboratory research to clinical applications for patients with serious conditions.

1 investor

VAXIMM is a clinical-stage biopharmaceutical company developing oral T-cell immunotherapies for cancer, based on technology invented at UC San Diego. Its lead candidate VXM01 has been evaluated in clinical trials for indications such as pancreatic cancer, and the company operates as a subsidiary of OSR Health.

1 investor

VBI Vaccines is a biopharmaceutical company developing vaccine candidates using virus-like particle (VLP) platforms, including proprietary enveloped VLP and mRNA-launched eVLP technologies. It targets infectious diseases such as hepatitis B, COVID-19, and cytomegalovirus, as well as cancers including glioblastoma.

1 investor

VC Gene Therapy develops gene therapies, with a first pipeline using genome editing to treat autosomal dominant inherited retinal degenerative diseases and aiming to begin clinical trials. It is a subsidiary of Vision Care Inc. and part of the Vision Care Group, based in Kobe, Japan.

1 investor

Vcreate uses machine learning and single-cell sequencing screening assays to engineer human T-cell receptors (TCRs) for TCR-based therapies that target disease-specific antigens, including rare cancer mutations. Its platform screens hundreds of millions of TCR-antigen interactions to design receptors that activate against targets inside cells that are otherwise difficult to drug.

1 investor

Vectech develops AI-powered vector identification and surveillance technologies to support public health interventions and targeted mosquito control during disease outbreaks. The company serves public health organizations and disease prevention agencies globally.

1 investor

Vectron Biosolutions develops custom bacterial production strains for protein manufacturing, using proprietary technologies (VB Expression, VB Evolution, and VB Secretion) to engineer E. coli and other microorganisms for clients in the pharmaceutical and biotech industries.

1 investor

Vedana Therapeutics develops next-generation biologic medicines for migraine prevention, targeting PACAP and CGRP-independent pathways to address unmet needs in patients inadequately controlled by current therapies. The company focuses on the neurological and pharmaceutical sectors to serve the global migraine patient population.

1 investor

Veeva Clinical Platform is a cloud-based suite of connected applications for running clinical trials, covering clinical operations, clinical data, research sites, and patients. It serves biopharma sponsors, clinical research sites, and patients across trial management, data capture, and disclosures.

1 investor

Vega BioImaging develops a cancer diagnostic platform combining nanobead technology, optical imaging, and AI-powered analysis to enable quantitative detection of multiple cancer biomarkers simultaneously in tissue biopsies. The solution improves upon traditional immunohistochemistry methods for pathology laboratories and clinical research settings.

1 investor

Veirulence develops first-in-class non-antibiotic small molecule therapeutics that target bacterial virulence factors to treat resistant infections, with an initial focus on the WHO priority pathogen Pseudomonas aeruginosa. The company aims to address antimicrobial resistance in hospital-acquired bacterial infections.

1 investor

Vella Bioscience develops products for women's sexual and reproductive health using nano-encapsulated liposomal cannabidiol and liposome-based biotech to improve absorption of active ingredients, with a focus on female arousal, orgasm, and related pain. Its work spans the broader landscape of women's sexual and reproductive medicine.

1 investor

Velocity Bio is developing a biophysical assay platform designed to generate larger-scale, higher-quality data for early-stage drug discovery. The platform aims to shift early discovery from blind screening toward targeted molecular design.

1 investor

Velocity operates dedicated and embedded clinical research sites across the United States, providing the staff, equipment, study contracting, regulatory documentation, and business development support needed to run clinical trials. It partners with physician groups, independent practices, and health centers to add research capabilities and covers a wide range of therapeutic areas.

1 investor

Ventora Medical develops a neonatal airway pressure monitoring device for clinicians managing non-invasive respiratory support in newborn patients. The device provides continuous, accurate measurement of airway pressure delivered by CPAP and high-flow nasal cannula systems.

1 investor

Ventuno is a biotech company developing cancer therapies that leverage the immune system to target and eliminate cancer cells in difficult-to-treat tumors. The company focuses on immunotherapy approaches to advance cancer care.

1 investor

VeraMorph is a drug delivery company that has developed a proprietary oral drug delivery platform used to improve solubility and clinical translation of poorly soluble compounds. It works with pharmaceutical companies and is building a portfolio of clinically differentiated oral versions of approved drugs.

1 investor

Veranex is a contract research organization (CRO) for the medical device and diagnostics industry, combining product design, engineering, manufacturing, preclinical, clinical, regulatory, quality, and market-access services under one roof. It supports medtech companies from early concept through commercialization to bring devices and diagnostics to market.

1 investor

Verax Biomedical develops rapid bacterial contamination detection tests for blood products and tissues intended for transfusion and transplantation. The company serves blood banks, hospitals, and transfusion centers seeking to prevent infectious complications from bacterial growth in stored cellular materials.

1 investor

Verdel Instruments develops total correlation mass spectrometry (TOC-MS), a method using stored waveform ion radius modulation (SWIM) to generate MS/MS data for every analyte in a complex mixture. It sells upgrade kits that add this multi-dimensional capability to existing quadrupole-time of flight mass spectrometers, with optional ultraviolet photodissociation modifications.

1 investor

VERDOT designs and manufactures downstream purification solutions for biopharmaceutical and biotechnology companies to enable the production of therapeutic biologics. The company has over 70 years of manufacturing experience, with more than three decades focused on bioprocessing.

1 investor

Verge Labs develops vBx-1.0, a multi-modal biological foundation model trained on proprietary patient data that reasons about neurological disease at the patient level by integrating brain biology, blood biomarkers, and clinical trajectories. The model enables researchers and clinicians to predict patient disease progression and treatment response while deriving virtual brain biopsies from more accessible biological measurements.

1 investor

1 investor